Is BPC-157 or TB-500 Better for Injuries?

Nobody has tested BPC-157 against TB-500 in people, so neither one is proven better for injuries. BPC-157 has more injury research behind it: rat studies showing faster tendon, ligament and muscle healing, plus one small human knee report. TB-500 has almost no direct studies and leans on research into its parent protein, thymosin beta-4. Both are early-stage peptides. In July 2026 the FDA proposed keeping both off the list of ingredients pharmacies may compound from, with a final decision to follow its advisory committee's input.

What does BPC-157 do for tendon, ligament and muscle injuries?

In rats, BPC-157 helped injured tendons, ligaments and muscles heal. Rats with a cut Achilles tendon that got BPC-157 had tendons that held more load before failing and worked significantly better over 14 days. Their tendons also had smaller defects and were fully joined again (review of BPC-157 in soft tissue healing).

Researchers saw similar results in rats with a cut knee ligament (the MCL, on the inside of the knee) and in rats with crushed calf muscle. In the muscle study, BPC-157 helped whether it was given into the body or rubbed on as a cream.

BPC-157 was first isolated from human stomach juice in 1993. Researchers think it works in two ways. It may speed up fibroblasts, the cells that rebuild tendons and ligaments with fresh collagen. It may also encourage new blood vessels in tissues that heal slowly because they get little blood.

Human evidence is thin. A 2025 review of BPC-157 for musculoskeletal healing found only three published human studies. One was a small look-back study of knees, and the reviewers say it has many limitations. In that study, 14 of 16 patients reported significant knee pain relief 6 months to a year after a knee injection of BPC-157 alone or BPC-157 with thymosin beta-4.

Every published BPC-157 study has reported a benefit. The reviewers say that pattern could mean negative results went unpublished. Read the rat results as a reason for interest, not as proof that it works the same way in people.

What does TB-500 do for injuries, and is it the same as thymosin beta-4?

TB-500 is a lab-made peptide sold as a relative of thymosin beta-4. Thymosin beta-4 is a repair protein found throughout your body, and it is the most common protein in its family (2026 scoping review of thymosin beta-4 and TB-500). The FDA describes TB-500 as a fragment of thymosin beta-4.

Research on thymosin beta-4 ties it to the early steps of repair:

• drawing repair cells into an injury
• closing wounds
• growing new blood vessels
• calming inflammation

TB-500 itself has barely been studied. The 2026 review looked at 80 studies and found only one that tested TB-500 directly. That was a lab study of wound healing in fibroblasts. The human studies of thymosin beta-4 were mostly on eyes and skin wounds, not tendons or muscles.

The reviewers warn that thymosin beta-4 and products sold as TB-500 may not be interchangeable. Results for one should not be read as results for the other. When you see TB-500 marketed for injuries, most of the evidence behind it comes from thymosin beta-4 research.

Which one has more evidence for a tendon or muscle injury?

No study has compared BPC-157 and TB-500 head to head, so neither can be called better for healing. The difference is how much injury research each one has.

If you want one peptide for a tendon, ligament or muscle injury, BPC-157 has more injury-specific research behind it. Your clinical team can tell you whether BPC-157, TB-500 or the pair fits your injury.

Are BPC-157 and TB-500 safe, and can you still get them?

The FDA says it does not have enough information to know whether either peptide would cause harm in people. Animal testing of BPC-157 has not turned up a toxic dose. The FDA's view also affects how pharmacies can make both peptides.

The FDA says compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration." That means it may trigger an immune reaction when given some ways. The agency also says it "lacks sufficient information to know whether the drug would cause harm when administered to humans" (FDA on bulk drug substances).

The FDA says much the same about TB-500. It may cause an immune reaction "due to the potential for aggregation," meaning the peptide can clump. The FDA also says it "lacks important information regarding any safety issues."

In animal safety testing of BPC-157, researchers gave it at high doses and could not find a toxic or lethal dose. They saw no harm to developing babies, to genes or to tissue at the injection site. The 2025 reviewers still say BPC-157 should not be recommended for clinical muscle and joint care until well-designed human trials are published.

Lab studies show BPC-157 switches on blood vessel growth signals. Abnormal blood vessel growth can feed tumors, so the reviewers raised this as a theoretical concern. Tell your clinical team about any cancer history.

At a July 2026 meeting, the FDA proposed that neither BPC-157 nor TB-500 be added to the list of ingredients pharmacies may compound from. The FDA said it would make a final decision after considering its advisory committee's input.

If you compete in a drug-tested sport, both peptides are banned at all times. BPC-157 is banned as an unapproved substance. TB-500 is banned as a thymosin beta-4 derivative.

How much do BPC-157 and TB-500 cost, and how do you take them?

Zepym sells the BPC-157 and TB-500 blend at three prices:

• $329 a month, month to month
• $259 a month on a 3-month plan
• $229 a month on a 6-month plan

Zepym's blend is a small injection under the skin. The label reads: "Inject 20 units (0.6 mg) subcutaneously in the morning once daily 5 days per week for 4 weeks." The physician sets each patient's dose.

Women want to know how fast an injury feels different. One man on Reddit had six years of shoulder pain and started with BPC-157 alone. He wrote: "By week two, I was going about my day and suddenly realized the shoulder didn't hurt." After his 40-day course he wrote: "I'd say about 60–70% of the pain had vanished, though I still had the odd bad morning." He added TB-500 afterward.

A peptide does not replace the rehab your injury needs. Keep up your physical therapy and strength work while you try one.

Take the quiz so your clinical team can look at your injury, your health history and your goals. They will tell you whether BPC-157, TB-500 or the pair fits your plan.